<SEC-DOCUMENT>0001104659-24-050307.txt : 20240423
<SEC-HEADER>0001104659-24-050307.hdr.sgml : 20240423
<ACCEPTANCE-DATETIME>20240423070047
ACCESSION NUMBER:		0001104659-24-050307
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240423
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240423
DATE AS OF CHANGE:		20240423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theriva Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		24862661

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Synthetic Biologics, Inc.
		DATE OF NAME CHANGE:	20120305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2412300d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:syn="http://syntheticbiologics.com/20240423">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_syn_syntheticbiologics.com_20240423 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20240423_20240423 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0000894158 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000004" name="dei:EntityCentralIndexKey">0000894158</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="syn-20240423.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-04-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-23</xbrli:startDate>
        <xbrli:endDate>2024-04-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_903_edei--DocumentType_c20240423__20240423_zyAE9VZPN3X1"><ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): <span id="xdx_902_edei--DocumentPeriodEndDate_c20240423__20240423_zneX01EOQan8"><ix:nonNumeric contextRef="AsOf2024-04-23" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">April 23, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityRegistrantName_c20240423__20240423_zmnTew52FDFh"><ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000011" name="dei:EntityRegistrantName">THERIVA BIOLOGICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20240423__20240423_zLcEr0CZXU14"><ix:nonNumeric contextRef="AsOf2024-04-23" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 34%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90A_edei--EntityFileNumber_c20240423__20240423_z6qOanaMLox4"><ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000013" name="dei:EntityFileNumber">001-12584</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20240423__20240423_zZXqwLEfueth"><ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000014" name="dei:EntityTaxIdentificationNumber">13-3808303</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</p></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">(Commission File No.)</span></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20240423__20240423_z3YCf9LPpEbd"><ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000015" name="dei:EntityAddressAddressLine1">9605 Medical Center Drive</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine2_c20240423__20240423_zvznEQxJtGwf"><ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 270</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityAddressCityOrTown_c20240423__20240423_zXt3ufqf2zGd"><ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000017" name="dei:EntityAddressCityOrTown">Rockville</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20240423__20240423_zqXlqflaUxmf"><ix:nonNumeric contextRef="AsOf2024-04-23" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20240423__20240423_z7Pad4lgkzHj"><ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000019" name="dei:EntityAddressPostalZipCode">20850</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_905_edei--CityAreaCode_c20240423__20240423_zGmjFHqz2Pl5"><ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000020" name="dei:CityAreaCode">301</ix:nonNumeric></span>) <span id="xdx_901_edei--LocalPhoneNumber_c20240423__20240423_zZAOoMnEGjOg"><ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000021" name="dei:LocalPhoneNumber">417-4364</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_90D_edei--WrittenCommunications_c20240423__20240423_zYMCirvm8Kcc"><ix:nonNumeric contextRef="AsOf2024-04-23" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_908_edei--SolicitingMaterial_c20240423__20240423_z0CfKrEfZBu3"><ix:nonNumeric contextRef="AsOf2024-04-23" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act
(17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_902_edei--PreCommencementTenderOffer_c20240423__20240423_zJ0Q7eTHe1pe"><ix:nonNumeric contextRef="AsOf2024-04-23" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20240423__20240423_zMJd3RbVm94b"><ix:nonNumeric contextRef="AsOf2024-04-23" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 33%; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 34%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20240423__20240423_z7IFf02763B3"><ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000026" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20240423__20240423_zPa7YPlF4ov4"><ix:nonNumeric contextRef="AsOf2024-04-23" id="Fact000027" name="dei:TradingSymbol">TOVX</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--SecurityExchangeName_c20240423__20240423_zd2RkFny6qp9"><ix:nonNumeric contextRef="AsOf2024-04-23" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20240423__20240423_zoZaSfSVzAq8"><ix:nonNumeric contextRef="AsOf2024-04-23" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7.01. Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On April 23, 2024, Theriva
Biologics, Inc. (the &#8220;Company&#8221;) issued a press release announcing positive topline data from the investigator sponsored Phase
1 Trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma. Safety and clinical outcomes support the therapeutic
potential of VCN-01 in retinoblastoma and emphasize VCN-01&#8217;s potential for use in diverse cancer. The Monitoring Committee determined
that the trial results were positive, and therefore, the Company will receive an exclusive, worldwide license, and related patents from
Sant Joan de D&#233;u-Barcelona Children&#8217;s Hospital for the treatment of pediatric patients with advanced retinoblastoma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Key Takeaways: </b>Patients received two intravitreal injections
of VCN-01, 14 days apart, at a dose of either 2 x 10<sup>9</sup> vp/eye (n=1) or 2 x 10<sup>10</sup> vp/eye (n=8). The data for 9 evaluable
patients were reviewed by the study Monitoring Committee who agreed that the trial had a positive outcome:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: top"><td style="width: 20px"/><td style="width: 20px">&#9679;</td><td><b>Safety</b>:
VCN-01 was well tolerated after intravitreal administration at the 2 doses and the most frequently reported treatment-related adverse
events were Grade 1 or 2. There were no dose limiting toxicities and no ocular or systemic toxicities equal to or greater than Grade
3 during the evaluation period.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 60px"/><td style="width: 20px">o</td><td>Some
degree of ocular inflammation and associated turbidity was observed after VCN-01 injection. Inflammation was managed, and vitreous haze
improved in some cases, by local and systemic administration of anti-inflammatory drugs.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 20px"/><td style="width: 20px">&#9679;</td><td><b>Antitumor
effects:</b> intravitreal VCN-01 demonstrated promising antitumor activity and did not appear to change the retinal function.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: top"><td style="width: 60px"/><td style="width: 20px">o</td><td>Four
patients presented a response characterized by unequivocal improvement in vitreous seed density.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: top"><td style="width: 60px"/><td style="width: 20px">o</td><td>Eye
enucleation was avoided in 3 patients to date, one of whom has retained their eye after 4 years of follow-up.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01. Other Events.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 23, 2024, the Company issued a press
release announcing positive topline data from the investigator sponsored Phase 1 Trial of intravitreal VCN-01 in pediatric patients with
refractory retinoblastoma. Safety and clinical outcomes support the therapeutic potential of VCN-01 in retinoblastoma and emphasize VCN-01&#8217;s
potential for use in diverse cancer. The Monitoring Committee determined that the trial results were positive, and therefore, the Company
will receive an exclusive, worldwide license, and related patents from Sant Joan de D&#233;u-Barcelona Children&#8217;s Hospital for the
treatment of pediatric patients with advanced retinoblastoma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Key Takeaways: </b>Patients received two intravitreal injections
of VCN-01, 14 days apart, at a dose of either 2 x 10<sup>9</sup> vp/eye (n=1) or 2 x 10<sup>10</sup> vp/eye (n=8). The data for 9 evaluable
patients were reviewed by the study Monitoring Committee who agreed that the trial had a positive outcome:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: top"><td style="width: 20px"/><td style="width: 20px">&#9679;</td><td><b>Safety</b>:
VCN-01 was well tolerated after intravitreal administration at the 2 doses and the most frequently reported treatment-related adverse
events were Grade 1 or 2. There were no dose limiting toxicities and no ocular or systemic toxicities equal to or greater than Grade
3 during the evaluation period.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 60px"/><td style="width: 20px">o</td><td>Some
degree of ocular inflammation and associated turbidity was observed after VCN-01 injection. Inflammation was managed, and vitreous haze
improved in some cases, by local and systemic administration of anti-inflammatory drugs.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="width: 20px"/><td style="width: 20px">&#9679;</td><td><b>Antitumor
effects:</b> intravitreal VCN-01 demonstrated promising antitumor activity and did not appear to change the retinal function.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: top"><td style="width: 60px"/><td style="width: 20px">o</td><td>Four
patients presented a response characterized by unequivocal improvement in vitreous seed density.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: top"><td style="width: 60px"/><td style="width: 20px">o</td><td>Eye
enucleation was avoided in 3 patients to date, one of whom has retained their eye after 4 years of follow-up.</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 26.2pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%; padding-right: 0.8pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">(d)&#160;&#160;</span></td>
    <td style="width: 96%; padding-right: 0.8pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exhibits.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Exhibit<br/>
Number</b></span></td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 87%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><a href="tm2412300d2_ex99-1.htm">99.1</a></span></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif"><a href="tm2412300d2_ex99-1.htm"> Press Release issued by Theriva Biologics, Inc., dated April 23, 2024</a></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">104</span></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif">Cover Page Interactive Data File (embedded within the XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.2pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td>Dated: April 23, 2024</td>
  <td colspan="3"><b>&#160;THERIVA BIOLOGICS, INC.</b></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="width: 50%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 5%">&#160;</td>
    <td style="width: 40%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="padding-bottom: 1pt">&#160;</td>
  <td>By:</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">/s/ Steven A. Shallcross</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>Name:</td>
    <td>Steven A. Shallcross</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>Title:</td>
    <td>Chief Executive Officer and Chief Financial Officer</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2412300d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;<IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Theriva&trade; Biologics Announces Positive
Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&ndash;Phase 1 trial in collaboration with Sant
Joan de D&eacute;u-Barcelona Children&rsquo;s Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee&ndash;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&ndash;Safety and clinical outcomes support
the therapeutic potential of VCN-01 in retinoblastoma and emphasize VCN-01&rsquo;s potential for use in diverse cancer indications&ndash;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, April 23, 2024 &ndash;</B></FONT> Theriva&trade; Biologics (NYSE American: TOVX), a diversified clinical-stage company developing
therapeutics designed to treat cancer and related diseases in areas of high unmet need, <FONT STYLE="color: windowtext">today </FONT>announced
positive topline data from the investigator sponsored Phase 1 trial conducted by collaborators at Sant Joan de D&eacute;u-Barcelona Children&rsquo;s
Hospital (SJD). The Phase 1 trial was designed to evaluate the safety and tolerability of two intravitreal injections of Theriva&rsquo;s
investigational oncolytic adenovirus VCN-01 in patients (n=9) with intraocular retinoblastoma that is refractory to chemotherapy or radiotherapy,
and for whom enucleation was the only recommended treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Results from the investigator sponsored
trial further validate VCN-01&rsquo;s unique mechanism of action and therapeutic potential to improve patient outcomes in otherwise refractory
cancers,&rdquo; said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. &ldquo;We look forward to building on the encouraging
safety profile and antitumor activity, which further supports and informs the design of our proposed Phase 2 clinical trial. The Monitoring
Committee determined that the trial results were positive, and therefore, Theriva will receive an exclusive, worldwide license, and related
patents from SJD for the treatment of pediatric patients with advanced retinoblastoma. The positive completion of this trial is an important
step in refining our clinical strategy for VCN-01 as an adjunct to chemotherapy to address the high unmet need in this underserved indication.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Key Takeaways: </B>Patients received two intravitreal injections
of VCN-01, 14 days apart, at a dose of either 2 x 10<SUP>9</SUP> vp/eye (n=1) or 2 x 10<SUP>10</SUP> vp/eye (n=8). The data for 9 evaluable
patients were reviewed by the study Monitoring Committee who agreed that the trial had a positive outcome:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>Safety</B>: VCN-01 was well tolerated after intravitreal administration at the 2 doses and the most frequently reported treatment-related
adverse events were Grade 1 or 2. There were no dose limiting toxicities and no ocular or systemic toxicities equal to or greater than
Grade 3 during the evaluation period.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD>Some degree of ocular inflammation and associated turbidity was observed after VCN-01 injection. Inflammation was managed, and vitreous
haze improved in some cases, by local and systemic administration of anti-inflammatory drugs.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>Antitumor effects:</B> intravitreal VCN-01 demonstrated promising antitumor activity and did not appear to change the retinal function.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD>Four patients presented a response characterized by unequivocal improvement in vitreous seed density.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD>Eye enucleation was avoided in 3 patients to date, one of whom has retained their eye after 4 years of follow-up.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Retinoblastoma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Retinoblastoma is a tumor that originates in the retina and is the
most common type of eye cancer in children. It occurs in approximately 1/14,000 - 1/18,000 live newborns and accounts for 15% of the tumors
in the pediatric population &lt; 1 year old. The average age of pediatric patients at diagnosis is 2, and it rarely occurs in children
older than 6. In the U.S., retinoblastoma shows an incidence rate of 3.3 per 1,000,000 with only about 200 to 300 children diagnosed per
year according to the American Cancer Society. Preserving life and preventing the loss of an eye, blindness and other serious effects
of treatment that reduce the patient&rsquo;s life span or the quality of life, remains a challenge. In addition, children with retinoblastoma
have been more likely to lose their eye and die of metastatic disease in low-resource countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About VCN-01</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">VCN-01 is a systemically administered oncolytic adenovirus designed
to selectively and aggressively replicate within tumor cells and degrade the tumor stroma that serves as a significant physical and immunosuppressive
barrier to cancer treatment. This unique mode-of-action enables VCN-01 to exert multiple antitumor effects by (i) selectively infecting
and lysing tumor cells; (ii) enhancing the access and perfusion of co-administered chemotherapy products; and (iii) increasing tumor immunogenicity
and exposing the tumor to the patient&rsquo;s immune system and co-administered immunotherapy products. Systemic administration enables
VCN-01 to exert its actions on both the primary tumor and metastases. VCN-01 has been administered to over 80 patients in Phase 1 and
investigator-sponsored clinical trials of different cancers, including PDAC (in combination with chemotherapy), head and neck squamous
cell carcinoma (with an immune checkpoint inhibitor), ovarian cancer (with CAR-T cell therapy), colorectal cancer, and retinoblastoma
(by intravitreal injection). More information on these clinical trials is available at Clinicaltrials.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Theriva&trade; Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva&trade; Biologics (NYSE American: TOVX), is a diversified clinical-stage
company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a
new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve
access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient&rsquo;s
immune system. The Company&rsquo;s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively
within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer
treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal
(GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci)
and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT)
recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions
and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics&rsquo; website at <U>www.therivabio.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified
by terminology such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;expects,&rdquo;
 &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar expressions,
and include statements regarding regarding the therapeutic potential of VCN-01 to improve patient outcomes in otherwise refractory cancers,
building on the encouraging safety profile and antitumor activity, Theriva receiving an exclusive, worldwide license, and related patents
from SJD for the treatment of pediatric patients with advanced retinoblastoma and VCN-01 demonstrating promising antitumor activity Important
factors that could cause actual results to differ materially from current expectations include, among others, the Company&rsquo;s and
VCN&rsquo;s ability to reach clinical milestones when anticipated, generating clinical data that establishes VCN-01 may lead to improved
patient outcomes in otherwise refractory cancers; the Company&rsquo;s and VCN&rsquo;s product candidates demonstrating safety and effectiveness,
as well as results that are consistent with prior results; the ability to complete clinical trials on time and achieve the desired results
and benefits,; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory
requirements, regulatory limitations relating to the Company&rsquo;s and VCN&rsquo;s ability to promote or commercialize their product
candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing
or sale of the Company&rsquo;s and VCN&rsquo;s products, developments by competitors that render such products obsolete or non-competitive,
the Company&rsquo;s and VCN&rsquo;s ability to maintain license agreements, the continued maintenance and growth of the Company&rsquo;s
and VCN&rsquo;s patent estate, the ability to continue to remain well financed, and other factors described in the Company&rsquo;s Annual
Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2023 and its other filings with the SEC, including subsequent periodic reports
on Forms 10-Q and current reports on Form&nbsp;8-K. The information in this release is provided only as of the date of this release, and
Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information,
future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chris Calabrese<BR>
LifeSci Advisors, LLC<BR>
ccalabrese@lifesciadvisors.com<BR>
917-680-5608</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Source: Theriva Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>syn-20240423.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa2AObOdzZR+2YkxtmB3bRn6by4pVws5cybzLMG2gQYB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:syn="http://syntheticbiologics.com/20240423" elementFormDefault="qualified" targetNamespace="http://syntheticbiologics.com/20240423">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://syntheticbiologics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="syn-20240423_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="syn-20240423_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>syn-20240423_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>syn-20240423_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://syntheticbiologics.com/role/Cover" xlink:href="syn-20240423.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://syntheticbiologics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140375827072112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 23, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 23,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERIVA BIOLOGICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000894158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3808303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9605 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-4364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TOVX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
M%SB76 =!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    "  7.)=8*--L ^X    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  7.)=8F5R<(Q &
M  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( !<XEUB"X>)S9P0  "D1   8              " @0T(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  7.)=8GZ ;\+$"
M  #B#   #0              @ &J#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( !<XEUB7BKL<P    !,"   +              "  88/  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( !<XEUBJQ"(6,P$  "("   /              "
M 6\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  7.)=8)!Z;HJT   #X
M 0  &@              @ '/$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    "  7.)=899!YDAD!  #/ P  $P              @ &T
L$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #^$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2412300d2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://syntheticbiologics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>syn-20240423.xsd</File>
    <File>syn-20240423_lab.xml</File>
    <File>syn-20240423_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2412300d2_8k.htm">tm2412300d2_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2412300d2_8k.htm": {
   "nsprefix": "syn",
   "nsuri": "http://syntheticbiologics.com/20240423",
   "dts": {
    "schema": {
     "local": [
      "syn-20240423.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "syn-20240423_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syn-20240423_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2412300d2_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://syntheticbiologics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-04-23",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2412300d2_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-04-23",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2412300d2_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001104659-24-050307-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-050307-xbrl.zip
M4$L#!!0    ( !<XEU@<E$&O+0,  /X+   0    <WEN+3(P,C0P-#(S+GAS
M9+56VW+:,!!][TS_0?5KQAA,2!L"R>0RR3!#FA::-,E+1Y87T$1(KB0'R-=7
M\H6;@0!M_22OSCF[J]V5W3@;#QEZ!:FHX$VG4BH["#@1(>7]IG/?=<^[EZV6
M@\Y./WY YFE\<EUT38&%=70EB-OB/7&"ON(AU-$-<)!8"WF"'C"+K45<4P82
M78IAQ$"#V4@]U5&MY/L8N>X6N@_ 0R'O.ZVI[D#K2-4];S0:E;AXQ2,A7U2)
MB.%V@EV-=:RF:N5Q.7NVH]]21:;D WQ>&WT>=^AC'_B7N(VKS^0G]L_O@KOP
M[;ESX#^]C/7PHAIT^%$P.8P>1JI&)L%;^_;&[W]_NDA=-A09P! C4PRNFH[-
M+TMO5"T)V??\<KGB/=ZVNPG.28'U,:/\916\<GQ\["6[.;2 ' >2Y=)5SVX'
M6,%4V>S2#7C*E<:<+.!#/27,@VM>NKD I2NA1RF4YM 0EG *2*DO7CVS8?!^
M-0?&RNUC'$W!/:R"1#3;6  KJ8M 8UP&N7H2@5H)3;<6"1,^A9JU'H"F)*""
MB3XE27-:^&'YT%* P1"XOA9R> 4]'#,3T>\8,]JC$#I(8]D';;M-19C UKIY
M\V+.A>EQ,VB9Q=JBB)HFGAJ,R1:]+@6#'R8;9!=FR-YS9F'>I3!7AH-HV'32
MY9QL+AQ"CW*:!)&-5P6Y=IABF[I9)LR&MPPN*L4*PCM^FJPC"<K0D^3:QI#Q
M,\AF+L&,Q&POZBR^3<S,GA]IX:SS*>M #R736;=]U'04M?>CD]D&$GK&-N%N
M7MA?)NN2:;,<81UL&,ZD1,L'E?G-); D!97"Y6%$1 124]/K<S=$&CG5EOYM
MS@VR?I2#O'^7.,/!KHD;"K#_F'';ZA=3;7B+$V;>EZ>P8;(54B->&.Q-%VSZ
M:6@+DDAMH-@W-^>YUN16?+=:*8U5.(MTER!F)[!;$#EOCR#67/.K_*MU<+NP
M+53=UNF:S\5&IRLY'C"M<LO>(<Q_7/XBAD1FIR 6RAEJZ5D)*^J[IH[5ROIP
MWF,F[VJO)B BYEI.=FF$>4K^LE\U9K\%VQ4BQZ=%L'\*^[K=HPN*SE>U0,-+
MU<SR#U!+ P04    "  7.)=8H42:'_T*  " A@  %    '-Y;BTR,#(T,#0R
M,U]L86(N>&ULS9U=;^.X%8;O"_0_<-V;%AC'$P<MD.QD%QE/LC VFV1CSVS;
M1;&@)<810I,!)2?VOR\IB;)$\4A*BI*<BQF/^![JI?B8I+Z./_VXVU#T0D2:
M<'8^.C[Z.$*$13Q.V/I\]'4QOEC,YO,12C/,8DPY(^<CQD<__O#G/R'YY]-W
MXS&Z2@B-S] 7'HWG[(%_CV[PAIRAGP@C F=<?(^^8;I56_A50HE ,[YYIB0C
MLJ#8\1GZ^]%TBM%X/*#>;X3%7'R]GU?U/F;9<WHVF;R^OAXQ_H)?N7A*CR*^
M&5;A(L/9-JUJ^[C[6/XIPC_1A#V=J;]6."5('B^6GNW2Y'RD]EON]O7DB(OU
M9/KQX_'DG[]<+Z)'LL'CA*GC%I&1CE*UV.*.3T]/)WFIEK:4NY6@>A\G$VVG
MJEF6)AWZFI,T.4MS>]<\PEG>[;V[0:!"_6^L96.U:7P\'9\<'^W2>*0/?GX$
M!:?DGCR@O)EGV?Y9HI0FBH11N>U1D >[&2K$1,5/&%GCC,1J1Z=J1\?_4#OZ
M2[GY&J\('2&EE'R [3IMU%4&35R;O2,BX?$E>Y]K,]J3??G=$=G_T(!ZO/,F
M+'F&Z;O,UR.=V[XA[SOBASCW1UJ.\^1]1[H6^7^QG;4MO_GPVH\K51NOY:>&
M1;++Y 1&8FU25=$Q N=[R">&LNZJ=AXUZJ5J-.>BW78U,^9UIB0Z6O.724P2
M6??T1'T8JP]YL^5__IAQN1*X6*69P%&F:\J;<3ZRE$],2TIY(;0O+**>QI6*
M2<3EU/2<C6EQ&(OP!\$WUMV6K>:6PC_HJHHO#HO<!6"T(1,DY5L1D3?U2MTM
M=)1*1QLJ%6I)1=CXZV+T0ZY!OVO5?SY-#K4XZ&BY!-IN",N6LD9+"YK%KKK9
M9DKW<KTLB$ZV&#+[6$N0TCCNX NYXUCM_(KBM<6^4>ZJBZVV=!\W"H/H9)LC
MLY<K#5(B7]W\A:212)[5<KZK'0V9\TZWF&SU?4T3%@)M8S )-:VG@?V>K!,U
MM2@+ZOR6J(T=PQB@=SWT=]HVYP*K. AHAC@$9XMZ$*JB/'%TP=@6TWORS$47
M/DV9:VIL)DU8ZIJ@&+$8 ]$HM*@0>R+BUZT\8R>"[GNA:"E=<P%8-=$P9$'1
M8?<& E+)_3*R%)BEB1K >B%I2YV?;@!F6Z<>ABXH3@!S\"E)I?=+RN*14*KN
M!V#6/Z#8Q*YI@0V;O+2501$#V@.9R2-0&1(.-I<O:G4NETD#&UO3^X2G9;N+
MGTH<+$*FPX$4Y6%(Q7DBJ78;HH>AEM(U/8!5DQM#%A0Q=F\@*X4<Y7K_D%RR
M>! BE<X/((9-.QZE*$ XFL[ZT)!JGV!<)6F$:>'E2FY+.YIGT;H&!+1K0M(2
M!@4*Y Z$I0C0S.0A7H'Y%\%B&"XUI1]86E;MJ%2R $$QO?5AHO1>()EMA6BX
MAF<<6.KLIFR/V>K^+* + I0><ZV[MH6\ 8JG&>B294FV5\_3W6PW*R(LC6M+
M7+$!F=-,F.5!L "8,ADH9$CI4"'TTO/Z+@'+U$.,8'-,F5L"[":;%#0U 9%@
M-0;0<-#FSY1Z(6(F1R:!Z9S%9/<SV8/M:NG<,@'8;$)AB *BPNX,P*(4HUR-
MI-P+&'<BV6"Q7R11SU31%KI% S+:9,-4!00'8 V@HU2CQ7SF<R99XMT\EJ F
M#TGQ/'@/):#>+2P]MIO, .* T.EV"! D@U SRB=(<Q9Q\<QKCSO,^%8.@/L9
MC^$52D^46Z@&-:&)5F=(0( -\0E@U@C]4#R3@KAZCR>O *D:O!!W$<?R0*7E
M/]<)(\=@^ZU:MW1UV&TR91$&1!+L#N"G5'[0'Y"*0;<L%&BF;VCJU#\TTZ'0
M3(.&9OH>:):O/!!H3M[0U!/_T)P,A>8D:&A.W@6-['BO8\U,?KP52_YJ>S@;
M5'I!IFW5"LQ!%AXN+6]]L*@ M9Y1(3XQR1=6M^).\)>$1?"2&9)[ 08P;:7&
MT(:'CMU@'S_5@EC'>1UKBD5Y[Y=$R_R,,DV3]B&FT(0'2=-8[^!2J'TB<<?3
M#--_)\^=)^)VL1<\K(:MD#24X:%BL]<'3!&#9)"/$^L25W5#P_HJF5'N[A5@
MBZW#*\"UPB @L#EJOP)<7#TI1*Z[63$J" 9&A&:QLTZVF*KZN%861A>W#;5Z
M./]>2XV/+[+*[D+O'CF#'Q!H2USU-&1.][99'D2/ Z;,7L]E*-=YNAJO,DRD
M]N&[5N9L9C?M5!.Y+@BB=TTWK6E:ESONS=]$DLD]S_AFLV7E71[;<X. SE4O
M=]K4/6X5!='[7<Y,$DHM:HH=8['@-(F2+&'K7^3)ITBPK54VD2L@8(.:AK8B
M"!1 6R8'!R'22L<0W FB("2R(_*7 %5B(7'[\&"=[;O$KJ#H-ZSA@)5!0-)K
MSX1%!HRC6@0J0E >XQ>;>9INB7@3/)803PB!Y@&06OH0<8),]D)5!/ID:T&B
MK9P?]\?3U3+)J.WDLBUQ-B<!YJH9R2@/@@W E,E"7H;X SJ>_G7U-Z2C''?_
M#5\*K)+'+O:;%:= ]BFKRA4$'18U!Q9)$"C ODP:;C@JI:C0^LA.U3!K:8Y1
M[@H JRW=]8W"(#K=YJCUY6_TM:<A_W(7/4I3!'@AP2YS/?3;3)K#?UT3! (=
MQEHG):44::V/%Q(.4]:Z?Q&P]K8(6/<L M8A+@+60Q<!:V^+ +W;(D6(')=N
M5S198R Y8:?:-10=EDT^+-*@4(']@6-&%8(.,:XS6N8ISE1Z?K')]W\E/UA:
M">B<Y;3LLEDEM;2)@F"DRUDKK661=*XF1DKMFHMMG&0D+LQ<)0RS*,&T2H]H
MNR+>'^*,EH'F*W!Z]&$P-,QD"Z<B3.<RK (/J2Y=7THO'L#XC5#Z,^.O;$%P
MRAF)BVLIMCM%W7JW3\STV&X^- .(@\!IB$/@T1D5-'Y244B'E5?"O)#TC=,M
MR[#(WR47MI$)T+DE![#9),80!42*W1E 2"5&A=K/"]I%]HAJD57\[A#80$CN
M^'7M3M/&6]M6;4#,=!J$WN$N<WX<UL9%E*=7+#.B?B\B>2%?<(9+;V![(;GK
MERJ[3)MO4]JT 2'4:1!\?[**4:EBL&;*6\H8,9-+K37O>$K<4+E/'-.RV,X=
M4TD"PL/FJR.#C$!:ZX6%Q093^GF;)HRD\$1DJ-RR8+789*$A"8@%FR^ A5R*
MM-8+"Y<;(M9R>OM)\-?LL<S/"K8-4+MEH]-RDQ&K-"!6NOP!S.@05,3HE+I^
MX-D=$HH761;AEEJDCK$!S1K,M'0A 0.9:]%"2:2NM]SP#"TY^IH2E#T2=%G^
M#%T]$WQ1CZ]?&HDB]4)$L2IG,18VA+K$SG]U!#3<^NV1EC((D'KMP;]#4D4@
M'>*8FEO)L*B?Q^4FYAG9@&\[](>X(FBH><U1GSX(F@::-)G*PYHGUWD@4I$^
MLQG5D]O#2[R&R/'*V&+06!C7%$$P MJ"EL7UWPKPDSMONZ))=$4YAJ^R-#2.
M,^:U[1G)\@Z"@ AHNX)2Y.5"E"N]]/]GS)[$]CF+]G>"1X2HIZS2:K3JN_XV
M,-HM,V]J4I.F0:$!<?86OP"!ARI0K8X/M1G+Y\4\]="XRN;&HZ?%(Y8'\':;
MI6H&E<;@J^"=08YO+PQH@'&3H2,B(/0&V(1N..21* _]@(I@5(OV='Z6'K(
MDOCS_IX\$*'>.UB27?99[NBIXPQC0*SKL[?!S3%/YGH#@X#PK6ZA4[T4U2M
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MDJM6RFD:J8NPHL3???<MH$!1$M J,0WSO)5N[F,N1?!Y[+$5E"M*)ND3U?3
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MSLO@1Y/7?1Z)8.8SYI& @8/@%AB*([6N4U_(6>N#YSY/7@;,!,9#YHHA=^_
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MFTI;Y?3NDKTL3ZMLT,W8AR2MO+AJE8\59/V:\-#W62L9K[.&[[@^X'W6Y<'
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M'$YS#D;GLG!M<GF("J#R)$VEV5;VQ"TH/>K_='7\ZFB'?HAIOJ/FBOQ$;YM
MOO$(?JP^\S(X0>^=\?BKX/&&B6(M#5I']E"HJ58S[XV_G"^0"Q%R7*AU"YO(
M^(X4Y.#I L[!R9O+<W%Z?GEY=7)V=O'QW>O-W4W^O7]U<EK]_J^+L\'[UYN]
MW=V_;?Y1"CH(=9B*^L+0.-@E7X-Z#*ZKE1'9.8[G@D[B1:J)' W.JB< '6Z"
M%[M[/^B,8M[!V?$7;C>#-"*[,Y*I3N8'HC]/AR8!4U(=Q\8=AD"M6H]TUN=
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M"5OCY(=X!>^H##@65>8/+*EL'0 S*FU(O2/369+(4CT:2$^-1*Q([V%5+ O
MHZ;G8D_/H+'*J#XT]T2I6ZI4AJV#:S)W@@:_K8**^(&"%8K\^JLD=9$'WUU/
M"%S>:*VR69-;J%J+&<) ( R35,";4:?/Y[L@(8"&!214PJ+HG)%GB38J@L$5
MB9>["\]#\SJA-8JUFAU+4W06+=OEM@M#<ZPA]8*@MFI($;>3DEW U=G)*41
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M4$L! A0#%     @ %SB76*%$FA_]"@  @(8  !0              ( !6P,
M '-Y;BTR,#(T,#0R,U]L86(N>&UL4$L! A0#%     @ %SB76.BLU0%=!P
MZ%<  !0              ( !B@X  '-Y;BTR,#(T,#0R,U]P<F4N>&UL4$L!
M A0#%     @ %SB76',XS_?G%   2W\  !(              ( !&18  '1M
M,C0Q,C,P,&0R7SAK+FAT;5!+ 0(4 Q0    ( !<XEUAM06YGF!(  *)!   6
M              "  3 K  !T;3(T,3(S,#!D,E]E>#DY+3$N:'1M4$L%!@
0   %  4 1@$  /P]      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>tm2412300d2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="syn-20240423.xsd" xlink:type="simple"/>
    <context id="AsOf2024-04-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-04-23" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-04-23" id="Fact000004">0000894158</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-04-23" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-04-23" id="Fact000010">2024-04-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-04-23" id="Fact000011">THERIVA BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-04-23" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-04-23" id="Fact000013">001-12584</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-04-23" id="Fact000014">13-3808303</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-04-23" id="Fact000015">9605 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-04-23" id="Fact000016">Suite 270</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-04-23" id="Fact000017">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-04-23" id="Fact000018">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-04-23" id="Fact000019">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-04-23" id="Fact000020">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-04-23" id="Fact000021">417-4364</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-04-23" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-04-23" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-04-23" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-04-23" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-04-23" id="Fact000026">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-04-23" id="Fact000027">TOVX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-04-23" id="Fact000028">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-04-23" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
